Xilio Therapeutics Inc.

NASDAQ: XLO · Real-Time Price · USD
0.70
-0.00 (-0.38%)
At close: Aug 15, 2025, 3:59 PM
0.70
-0.72%
After-hours: Aug 15, 2025, 06:18 PM EDT

Xilio Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
6.34M n/a n/a n/a
Cost of Revenue
n/a 1.9M 1.85M 1.5M
Gross Profit
6.34M -1.9M -1.85M -1.5M
Operating Income
-60.58M -79.13M -89.15M -75.04M
Interest Income
n/a n/a n/a 600.00
Pretax Income
-58.24M -76.4M -88.22M -75.8M
Net Income
-58.24M -76.4M -87.3M -74.3M
Selling & General & Admin
24.78M 27M 29.95M 23.86M
Research & Development
41.21M 52.14M 59.2M 51.19M
Other Expenses
937K n/a 927K -756K
Operating Expenses
66.93M 79.13M 89.15M 75.04M
Interest Expense
n/a n/a n/a 600K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
66.93M 79.13M 89.15M 75.04M
Income Tax Expense
n/a n/a -927K -1.5M
Shares Outstanding (Basic)
53.51M 27.5M 27.39M 27.36M
Shares Outstanding (Diluted)
53.51M 27.5M 27.39M 27.36M
EPS (Basic)
-1.09 -2.78 -3.19 -2.72
EPS (Diluted)
-1.09 -2.78 -3.19 -2.72
EBITDA
-58M -73.8M -85.58M -73.7M
EBIT
-59.65M -75.7M -87.42M -75.2M
Depreciation & Amortization
1.64M 1.9M 1.85M 1.5M